Ibodutant

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ibodutant
Ibodutant structure.svg
Systematic (IUPAC) name
Nα-[(1-{[(6-methyl-1-benzothien-2-yl)carbonyl]amino}cyclopentyl)carbonyl]-N-{[1-(tetrahydro-2H-pyran-4-ylmethyl)piperidin-4-yl]methyl}-D-phenylalaninamide
Clinical data
Oral
Identifiers
None
PubChem CID 11527495
ChemSpider 9702281 N
UNII 1H7RSQ28BJ YesY
Synonyms 6-methyl-N-[1-[[(2R)-1-[[1-(oxan-4-ylmethyl)piperidin-4- yl]methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamide
Chemical data
Formula C37H48N4O4S
644.866 g/mol
 N (what is this?)  (verify)

Ibodutant is a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. As of March 2015, it is undergoing a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe(the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study in women is ongoing.[1]

See also[edit]

References[edit]

  1. ^ "CLINICAL TRIALS DATABASE". Menarini Group. Retrieved 11 March 2015. 
  • H. Spreitzer (May 26, 2008). "Neue Wirkstoffe - Ibodutant". Österreichische Apothekerzeitung (in German) (11/2008): 541. 
  • S. Giuliani, M. Altamura, C. A. Maggi. "Ibodutant. Tachykinin NK2 receptor antagonist, Treatment of irritable bowel syndrome.". Drugs of the Future 33 (2): 111–115.